세계의 개 관절염 치료 시장 : 치료 유형별, 관절염 유형별, 예측(2024-2032년)

Canine Arthritis Treatment Market size is expected to register over 4.7% CAGR between 2024 and 2032. With the rising number of aging dogs, the incidence of arthritis, which is a common disease in older dogs, is increasing. This is further driving the demand for effective treatments to relieve pain and improve the quality of life of the sick pets. As per Arthritis Foundation, canine arthritis affects one out of every five dogs. Pet owners have grown increasingly aware of the symptoms of arthritis and the importance of early intervention, leading to the strong demand for veterinary consultations, diagnostic services, and treatment solutions.

Growing technological advancements and innovations in veterinary medicine are also influencing the market growth. The development of new drugs, including non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying osteoarthritis drugs (DMOADs), and regenerative therapies, such as stem cell therapy, is offering veterinarians a wider range of options for effective treatment of canine arthritis. The increasing availability and popularity of alternative therapies like physical therapy, hydrotherapy and joint health supplements will further expand the market growth.

The canine arthritis treatment industry is classified into treatment type, arthritis type and region.

Based on treatment type, the market size from the surgical procedure treatment type segment is slated to witness significant CAGR during 2024-2032, owing to advancements in veterinary surgical techniques and the increasing acceptance of surgical interventions. Procedures, such as arthroscopy, joint surgery and corrective osteotomies are becoming more common as they significantly improve mobility and quality of life in dogs with advanced arthritis. These operations are supported by better diagnostic tools and post-operative care for improving their success and results.

Canine arthritis treatment industry from the rheumatoid arthritis type segment is predicted to record decent growth rate through 2032, driven by the increasing recognition of autoimmune arthritis conditions in dogs and the development of targeted therapies to address them. Rheumatoid arthritis, although less common in dogs than osteoarthritis, can cause severe pain and joint damages if left untreated. With developments in veterinary medicine, understanding of the mechanisms underlying autoimmune arthritis in dogs is increasing, leading to the development of new treatment options, such as disease-modifying drugs and immunosuppressants.

Europe canine arthritis treatment industry is poised to depict sustained growth during 2024-2032, attributed to stringent regulatory standards for ensuring the safety and efficacy of veterinary pharmaceuticals along with the growing minimally invasive surgeries. The well-established veterinary infrastructure and high pet ownership rate are increasing the demand for specialized arthritis treatment. The strong emphasis on preventive treatment and the growing awareness of European pet owners about arthritis treatment strategies are also fueling the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing awareness regarding canine health
    • 3.2.1.2 Growing cases of arthritis and related disorders
    • 3.2.1.3 Advancement in technology for treatment
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Drugs
  • 5.2.1 Non-steroidal anti-inflammatory drugs (NSAID's)
  • 5.2.2 Corticosteroids
  • 5.2.3 Opioid pain relievers
  • 5.2.4 Other drugs
• 5.3 Supplements
  • 5.3.1 Glucosamine
  • 5.3.2 Chondroitin
  • 5.3.3 Methylsulfonylmethane
  • 5.3.4 Other supplements
  • 5.3.5 Drugs and supplements market, by route of administration
    • 5.3.5.1 Oral
    • 5.3.5.2 Injectable
    • 5.3.5.3 Other routes of administration
  • 5.3.6 Drugs and supplements market, by distribution channel
    • 5.3.6.1 Veterinary hospital pharmacies
    • 5.3.6.2 Retail pharmacies
    • 5.3.6.3 Online pharmacies
• 5.4 Surgical procedures
• 5.5 Other treatment types

Chapter 6 Market Estimates and Forecast, By Arthritis Type, 2021 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Osteoarthritis
• 6.3 Osteochondrosis
• 6.4 Rheumatoid arthritis
• 6.5 Traumatic arthritis

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Rest of Latin America
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 Rest of Middle East and Africa

Chapter 8 Company Profiles

• 8.1 American Regent, Inc.
• 8.2 Bayer AG
• 8.3 Boehringer Ingelheim Animal Health
• 8.4 CEVA Santé Animale
• 8.5 Dechra Pharmaceuticals PLC
• 8.6 Elanco Animal Health
• 8.7 Nutramax Laboratories Veterinary Sciences, Inc.
• 8.8 Vetoquinol SA
• 8.9 VetStem, Inc.
• 8.10 Virbac
• 8.11 Zoetis Inc.